 |
|
Effects of Hormone Replacement Therapy on Bone Mineral Density in Postmenopausal Women With Primary Hyperparathyroidism
Four-Year Follow-up and Comparison With Healthy Postmenopausal Women
Brandon J. Orr-Walker, MBChB;
Margaret C. Evans, BSc;
Judy M. Clearwater;
Anne Horne, MBChB;
Andrew B. Grey, MBChB;
Ian R. Reid, MD
Arch Intern Med. 2000;160:2161-2166.
Background Long-term treatment of patients with asymptomatic primary hyperparathyroidism remains controversial, but the presence of osteoporosis is regarded as an indication for parathyroidectomy. Hormone replacement therapy (HRT) is a possible alternative therapy in osteopenic postmenopausal women with the disorder, and results of short-term studies suggest a beneficial effect on bone mass comparable to that achieved by parathyroidectomy. Longer-term data are required to further assess the efficacy of this treatment in chronic stable primary hyperparathyroidism.
Methods We report the results of the extension from 2 to 4 years of a randomized, placebo-controlled trial of HRT in postmenopausal women with primary hyperparathyroidism. Of 23 postmenopausal women with primary hyperparathyroidism, 11 received active HRT with conjugated equine estrogen, 0.625 mg/d, and medroxyprogesterone acetate, 5 mg/d, and 12 received placebo. Bone mineral density was measured throughout the skeleton at 6-month intervals using dual-energy x-ray absorptiometry in these women and in 50 normocalcemic age-matched control subjects. None of the 23 patients withdrew during the extension period.
Results Changes in bone mineral density were more positive in those taking HRT than placebo, with the between-group differences at 4 years being 4.6% in the total body, 7.5% in the lumbar spine, 7.4% in the femoral neck, 8.2% in the femoral trochanter, 6.8% in the legs, and 7.0% in the forearm (P<.01). At skeletal sites composed predominantly of cortical bone, there was a progressive divergence of the 2 groups. Biochemical markers of bone turnover remained lower throughout the study in women taking HRT. When rates of bone loss were compared between the placebo group and healthy women of comparable age, bone loss tended to be more marked throughout the skeleton in women with hyperparathyroidism, but only in the total body and its legs subregion was this difference significant.
Conclusions Hormone replacement therapy is efficacious in the long-term management of osteopenia in postmenopausal women with primary hyperparathyroidism and thus represents an important new therapeutic option for asymptomatic patients who do not have other indications for surgery. Bone loss seems to be accelerated in untreated primary hyperparathyroidism.
From the Department of Medicine, University of Auckland, Auckland, New Zealand.
RELATED ARTICLE
Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2000;160(14):2228.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Using biochemical markers of bone turnover in clinical practice.
SINGER and EYRE
Cleveland Clinic Journal of Medicine 2008;75:739-750.
ABSTRACT
| FULL TEXT
Alendronate in Primary Hyperparathyroidism: A Double-Blind, Randomized, Placebo-Controlled Trial
Khan et al.
J. Clin. Endocrinol. Metab. 2004;89:3319-3325.
ABSTRACT
| FULL TEXT
Normocalcemic Primary Hyperparathyroidism: Evidence for a Generalized Target-Tissue Resistance to Parathyroid Hormone
Maruani et al.
J. Clin. Endocrinol. Metab. 2003;88:4641-4648.
ABSTRACT
| FULL TEXT
Oral Alendronate Increases Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism
Chow et al.
J. Clin. Endocrinol. Metab. 2003;88:581-587.
ABSTRACT
| FULL TEXT
A Randomized Controlled Trial of Estrogen Replacement Therapy in Long-Term Users of Depot Medroxyprogesterone Acetate
Cundy et al.
J. Clin. Endocrinol. Metab. 2003;88:78-81.
ABSTRACT
| FULL TEXT
V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women
Wells et al.
Endocr. Rev. 2002;23:529-539.
FULL TEXT
Evidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women
Masiukiewicz et al.
J. Clin. Endocrinol. Metab. 2002;87:2892-2898.
ABSTRACT
| FULL TEXT
Ultrasound guided laser ablation of a parathyroid adenoma
Bennedbak et al.
Br. J. Radiol. 2001;74:905-907.
ABSTRACT
| FULL TEXT
Hormone Replacement Therapy and Prevention of Nonvertebral Fractures: A Meta-analysis of Randomized Trials
Torgerson and Bell-Syer
JAMA 2001;285:2891-2897.
ABSTRACT
| FULL TEXT
|
